Can-Fite BioPharma annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma EBITDA Growth & History (CANF)
Can-Fite BioPharma's calculated EBITDA was −$9.9M for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.9M | −$1.8M | — |
| 2024 | 2024-12-31 | −$8.1M | $57,000 | — |
| 2023 | 2023-12-31 | −$8.2M | $1.9M | — |
| 2022 | 2022-12-31 | −$10.1M | $2.7M | — |
| 2021 | 2021-12-31 | −$12.8M | $1.3M | — |
| 2020 | 2020-12-31 | −$14.1M | −$2.1M | — |
| 2019 | 2019-12-31 | −$12.0M | −$6.6M | — |
| 2018 | 2018-12-31 | −$5.4M | — | — |
Can-Fite BioPharma quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Can-Fite BioPharma ebitda trends
Over the last five reported fiscal years, Can-Fite BioPharma's ebitda increased from −$14.1M to −$9.9M, a change of $4.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma filings at SEC.gov ↗